Impact of *ao-dake-humi*, Japanese traditional bamboo foot stimulator, on lower urinary tract symptoms, constipation and hypersensitivity to cold: a single-arm prospective pilot study

Tomonori Minagawa*, Tetsuichi Saitou, Toshiro Suzuki, Takahisa Domen, Hitoshi Yokoyama, Masakuni Ishikawa, Shiro Hirakata, Takashi Nagai, Masaki Nakazawa, Teruyuki Ogawa and Osamu Ishizuka

**Abstract**

**Background:** *Ao-dake-humi* is a traditional Japanese bamboo foot stimulator consisting of a half-pipe-shaped step made of bamboo used to stimulate the foot by stepping on it, and is commonly used to promote general health among the elderly in Japan. However, its efficacy has not been reported in the scientific literature. This study was performed to investigate the role of *ao-dake-humi* focusing on lower urinary tract symptoms (LUTS), constipation, and hypersensitivity to cold (HC).

**Methods:** Participants with LUTS, constipation, or HC were enrolled in this study. *Ao-dake-humi* was used twice a day for 28 days. Before and 28 days after starting *ao-dake-humi* use, international prostate symptom score (IPSS), quality-of-life (QoL) score, and overactive bladder symptom score (OABSS) were measured to evaluate the efficacy of *ao-dake-humi* on LUTS. To evaluate the objective efficacy of *ao-dake-humi* on LUTS, a frequency-volume chart (FVC) was plotted in LUTS patients for 3 days. A visual analogue scale (VAS) was used to evaluate the efficacy of *ao-dake-humi* on constipation (VAS-constipation) and HC (VAS-HC) in the participants with constipation or HC.

**Results:** A total of 24 participants were enrolled in this study. Twenty-one participants had LUTS, 11 had constipation, and 17 participants had HC. IPSS, especially storage-subscore, QoL score and OABSS, decreased significantly after use of *ao-dake-humi*. The use of *ao-dake-humi* increased maximal bladder capacity, resulting in a significant decrease in urinary frequency as determined from the FVC. In accordance with the results of VAS-constipation and VAS-HC, both constipation and HC were significantly relieved after *ao-dake-humi* use.

**Conclusion:** The results of this prospective pilot study indicated that *ao-dake-humi* is safe and has therapeutic efficacy in cases of LUTS, constipation and HC. The possibility of using *ao-dake-humi* as physical neuromodulation therapy was shown in the management of LUTS, constipation and HC.

**Trial registration:** UMIN000019333 (UMIN-CTR, Registered October-15-2015) retrospectively registered.

**Keywords:** *ao-dake-humi*, Lower urinary tract symptoms, Constipation, Hypersensitivity to cold, Urinary bladder, Colon, Skin, Neuromodulation, Reflexology
Background

Lower urinary tract symptoms (LUTS) and constipation are common problems, especially among the elderly [1]. On the other hand, skin sensation, especially to cold temperature, can be related to urinary bladder function. This symptomatic phenomenon is called “Hie-Shou” in Kampo-medicine (Japanese traditional medicine). Hie-Shou can be translated as hypersensitivity to cold (HC) [2]. HC induces several secondary symptoms, such as urinary urgency [2, 3]. Previously, we reported the importance of simultaneous management of LUTS, constipation and HC considering interaction among pelvic organs and skin [2] (Fig. 1a). On the other hand, foot massage and reflexology, are candidates for management of LUTS, constipation and HC [4–7]. The theory behind reflexology is that specific areas of foot match and are connected to specific organs of the body as shown in Fig. 1b. In Japan, a traditional bamboo foot stimulator called ao-dake-humi is commonly used to promote general health, and can be applied for management of LUTS, constipation, and HC as shown in Fig. 1a, b. However, the exact role of ao-dake-humi has not been proven. Therefore, we attempted to evaluate the safety and therapeutic efficacy of ao-dake-humi on LUTS, constipation and HC in this prospective pilot study.

Methods

This study was conducted between July 2013 and October 2015. The trial registration number is UMIN000019333 (UMIN-CTR, registration date is 15th Oct. 2015).

Eligible participants were >20 y.o. with LUTS, constipation and/or HC. LUTS patients with IPSS >13 or dissatisfied with current LUTS treatments were enrolled. Constipation and HC were evaluated according to self-description. Exclusion criteria were as follows: patients who could not make the decision themselves, those with a custom of receiving foot massage, those incapable of walking by themselves, and those with a history of recurrent urinary tract infection or bladder stones. All of the LUTS patients had already received some medical care in a hospital or a private clinic. In the process of the previous management of LUTS before enrolling this trial, urinary tract infection and cancer including prostate cancer had already excluded. Subjects were also excluded if they received surgery, diagnosed malignant disease, and used other medical interventions, such as drugs, within the previous 3 months. Participants could continue to take medication for LUTS and constipation to maintain the same condition before and after the study. However, the participants were not permitted to start or stop any intervention for LUTS, constipation or HC during the study.

Ao-dake-humi used in this study was made of bamboo, 40 cm in length, 8.5 cm in width, 4.5 cm in height, and almost 290 g in weight. The ao-dake-humi was brought to each participant’s home, and used twice a day, in the morning (after waking up) and evening (after taking a bath/shower or before going to bed) for 28 days. Holding something such as the wall, desk, or pillar, participants placed the arches of both feet on the ao-dake-humi, and then made repeated steps for 2 min in a set as shown in Fig. 2. Figure 2 includes the photographs with one of the author (T.M.). In accordance with the usual use of ao-dake-humi, steps were made 30–60 times/min, and participants could control the rate by themselves. If participants felt pain, they could reduce use to once a day. The rate of ao-dake-humi use was noted using a diary to evaluate the exact rate of use.

Fig. 1 a Relationship among urinary bladder, bowel, and skin sensation. Interactions of pelvic organs and skin sensation on pathological condition are briefly presented. Ao-dake-humi can be a therapeutic stimulator for management via simultaneous and indirect effect on lower urinary tract symptoms, constipation, and hypersensitivity to cold. This figure is modified schema shown in Ref #2. b A brief foot chart in reflexology. Only main and large areas are shown in this figure, and small parts are excluded for ease of understanding. Each area of the foot matches specific body parts, and is connected to promoting health of each part of the body by massage. The colon and urinary bladder are located in the arch area, which is the “hot spot” stimulated by ao-dake-humi.
intervention and harmfulness of *ao-dake-humi*. All of the participants recorded *ao-dake-humi* use as "done" or "none" in the diary. Total practical rate (= number of sets performed/(2 sets x 28 days)) was calculated in all of the participants. Moreover, adverse events were also evaluated in all of the participants during this research.

Before and 28 days after *ao-dake-humi*, international prostate symptom score (IPSS), quality-of-life (QoL) score, and overactive bladder symptom score (OABSS) were measured for evaluation of efficacy of *ao-dake-humi* on LUTS. IPSS storage, voiding, and postvoiding subscores were also assessed [8, 9]. Visual analogue scale (VAS) was used to evaluate the efficacy of *ao-dake-humi* on constipation (VAS-constipation) and HC (VAS-HC) in the enrolled participants with constipation or HC. VAS for constipation and HC were originally made, and were used to evaluate constipation and HC like pain scale. The line is 10 cm in length on the paper. The left edge of line is zero, and the right edge is maximal as 10 points. Zero means that patients have not any symptoms. And, 10 points means that patients have severe symptoms which patients can imagine maximally. Patients can place a vertical mark on the line to describe the severity of their symptoms intuitively. If the patients have severe symptoms, patients can put on the right part of the line. The length from zero to the point on which patients described the symptoms is treated as severity of symptoms, and the decrease or increase of length are considered as improvement or worsening of symptoms. IPSS, QoL score, OABSS, VAS-constipation, and VAS-HC was presented in Table 1 (written in English).

To evaluate the objective efficacy of *ao-dake-humi* on LUTS, a frequency-volume chart (FVC) was used. The FVC on 3 continuous days was recorded in all of the enrolled LUTS participants before and 28 days after starting *ao-dake-humi* use. The average total voided volume, daytime voided volume, nighttime voided volume, total urinary frequency in a day, daytime urinary frequency, and nighttime urinary frequency were evaluated for each day. The average mean voided volume, maximal voided volume, and minimal voided volume were also evaluated. Nighttime micturition was defined as micturition between 10:00 pm and 6:00 am.

All data are presented as the means ± SEM. The data were analysed using Excel-based statistical program file, Excel TouKei (Social Survey Research Information Co., Ltd., Tokyo, Japan), and $p < 0.05$ was considered to indicate significance. The changes before and after *ao-dake-humi* were analysed using the paired $t$ test.

**Results and discussion**

A total of 24 participants were enrolled in this study, and their characteristics are shown in Table 2. The results of subjective evaluation are shown in Table 3. The baseline of total IPSS, QoL score, and OABSS among LUTS patients is 14.7 ± 8.2, 4.3 ± 1.3, and 5.4 ± 3.6, respectively. Total IPSS, OABSS, and QoL score were improved after *ao-dake-humi* use in the participants with LUTS. In analysis of IPSS subscores, storage and postvoiding symptom subscores were significantly improved after *ao-dake-humi* use. As the first step to show the efficacy of *ao-dake-humi* on constipation and
Table 1  Medical interview sheet to evaluate lower urinary symptoms (LUTS) and visual analogue scale (VAS) to evaluate constipation and hypersensitivity to cold (HC). International prostate symptom score (IPSS), quality of life (QoL) score, and overactive bladder symptom score (OABSS) were used for LUTS. VAS were originally made to evaluate constipation and HC. Zero means that patients have not any symptoms. And, 10 points means that patients have severe symptoms which patients can imagine maximally.

### International prostate symptom score (IPSS)

| Question | Not at all | Less than 1 in 5 Times | Less than Half the Time | About Half the Time | More than Half the Time | Almost Always |
|----------|------------|------------------------|-------------------------|---------------------|-------------------------|--------------|
| Q1       | 0          | 1                      | 2                       | 3                   | 4                       | 5            |
| Q2       | 0          | 1                      | 2                       | 3                   | 4                       | 5            |
| Q3       | 0          | 1                      | 2                       | 3                   | 4                       | 5            |
| Q4       | 0          | 1                      | 2                       | 3                   | 4                       | 5            |
| Q5       | 0          | 1                      | 2                       | 3                   | 4                       | 5            |
| Q6       | 0          | 1                      | 2                       | 3                   | 4                       | 5            |
| Q7       | Nocturia   | 0                      | 1                       | 2                   | 3                       | 4            |

### Quality-of-life (QoL) score

| How would you feel about that? | Delighted | Pleased | Mostly Satisfied | Mixed | Mostly Dissatisfied | Unhappy | Terrible |
|--------------------------------|-----------|---------|------------------|-------|---------------------|---------|---------|
| If you were to spend the rest of your life with your urinary condition just the way it is now | 0         | 1       | 2                | 3     | 4                   | 5       | 6       |

### Overactive bladder symptom score (OABSS)

| Frequency | Score |
|-----------|-------|
| How many times do you typically urinate from waking in the morning until sleeping at night? | |
| < 7       | 0     |
| 7-14      | 1     |
| ≥ 15      | 2     |
| How many times do you typically wake up to urinate from sleeping at night until waking in the morning? | |
| 0         | 0     |
| 1         | 1     |
| ≥ 2       | 2     |
| ≥ 3       | 3     |
| How often do you have a sudden desire to urinate, which is difficult to defer? | |
| Not at all | 0 |
| Less than once a week | 1 |
| Once a week or more | 2 |
| About once a day | 3 |
| 2-4 times a day | 4 |
| 5 times a day or more | 5 |
| How often do you leak urine because you cannot defer the sudden desire to urinate? | |
| Not at all | 0 |
| Less than once a week | 1 |
| Once a week or more | 2 |
| About once a day | 3 |
| 2-4 times a day | 4 |
| 5 times a day or more | 5 |

### Visual analogue scale on constipation (VAS-constipation)

How severe is your constipation today? Place a vertical mark on the line below to indicate how bad your constipation is today.

[Zero (No constipation)](4.5) [MAX (10 points)](0.5)

### Visual analogue scale on hypersensitivity to cold (VAS-HC)

How severe is your HC today? Place a vertical mark on the line below to indicate how bad your HC is today.

[Zero (No HC)](4.5) [MAX (10 points)](0.5)
HC, evaluation was performed in this study using only VAS-constipation and VAS-HC. In accordance with the results, of the 11 participants with constipation, subjective VAS-constipation score was improved in -31.8% after ao-dake-humi use with statistical significance. Of the 17 participants with HC, subjective score was significantly improved in -21.9% of VAS-HC after ao-dake-humi use. The results of objective evaluation are shown in Table 4. Total urine volume did not change before and 28 days after starting ao-dake-humi use. Total and daytime urinary frequencies were decreased after ao-dake-humi use. These results may have been due to an increase in voided volume. Only the maximal voided volume increased significantly after ao-dake-humi use; mean and minimal voided volumes were also not significantly increased.

Previous reports indicated that a decrease in environmental temperature induces numerous physiological responses, including increased urinary frequency in both humans and animals [10, 11]. Previously, we reported the relationship between HC and LUTS, and the efficacy of simultaneous approaches using Kampo-medicine [2]. In this study, 60% of the enrolled participants had both LUTS and HC, and the efficacy of ao-dake-humi on HC was revealed subjectively. Moreover, constipation was also improved after ao-dake-humi use. Five of 11 participants with constipation had received drug treatment before starting this research. These results indicated that ao-dake-humi is a candidate therapeutic option to manage LUTS, constipation and HC. However, HC and constipation were evaluated on the basis of self-description using VAS. A further RCT with larger number of participants is needed.

Ao-dake-humi is a Japanese traditional home health appliance based on the theory of reflexology, and can be used at home to promote general health in daily use. 

---

### Table 2 Participant characteristics

| Total | Sex | Male | Female | Age (y.o.) | 65.2 ± 16.3 | Body mass index (kg/m 2) | 21.8 ± 2.2 |
|-------|-----|------|--------|-----------|-------------|------------------------|-------------|

### Distribution of LUTS, constipation, and HC

| LUTS | Constipation | HC | Only LUTS | Only Constipation | Only HC | LUTS and constipation | LUTS and HC | Constipation and HC | LUTS, constipation, and HC |
|------|--------------|----|-----------|------------------|--------|---------------------|-------------|-------------------|---------------------------|
| LUTS | 21           |    |           |                  |        |                     |             |                   |                           |
| Constipation | 11 |    |           |                  |        |                     |             |                   |                           |
| HC | 17 |    |           |                  |        |                     |             |                   |                           |
| Only LUTS | 5 |    |           |                  |        |                     |             |                   |                           |
| Only Constipation | 0 |    |           |                  |        |                     |             |                   |                           |
| Only HC | 1 |    |           |                  |        |                     |             |                   |                           |
| LUTS and constipation | 2 |    |           |                  |        |                     |             |                   |                           |
| LUTS and HC | 7 |    |           |                  |        |                     |             |                   |                           |
| Constipation and HC | 2 |    |           |                  |        |                     |             |                   |                           |
| LUTS, constipation, and HC | 7 |    |           |                  |        |                     |             |                   |                           |

### Past history

| Benign prostatic hyperplasia | 8 |
| Hypertension | 3 |
| Diabetes mellitus | 1 |

### Medication

| Alpha 1-adrenoceptor antagonist | 8 |
| Anticholinergic drug | 1 |
| Beta 3-adrenoceptor agonist | 3 |
| Cathartic drug | 5 |

---

Table 2. Participant characteristics

Characteristics of the enrolled patients in this study

**Table 3** Differences in lower urinary tract symptoms, constipation and hypersensitivity to cold (HC) before and after ao-dake-humi use

| LUTS | IPSS Total | VAS-constipation | VAS-HC |
|------|------------|-----------------|--------|
|      | −3.8       | −31.8           | −21.9  |
|      | 0.0002**   | 0.0073**        | 0.0158* |

**Table 3. Differences in lower urinary tract symptoms, constipation and hypersensitivity to cold (HC) before and after ao-dake-humi use**

LUTS lower urinary tract symptoms, IPSS international prostate symptom score, QOL quality of life, OABSS overactive bladder symptom score, HC hypersensitivity to cold, VAS Visual analogue scale

Subjective effect of ao-dake-humi on lower urinary tract and constipation and hypersensitivity to cold. Different before and after ao-dake-humi was shown.

*: p < 0.05, ** p < 0.01
**Table 4** Objective values before and after ao-dake-humi based on frequency-volume-chart (FVC)

| LUTS (N = 20)                  | Before         | After          | p value |
|--------------------------------|----------------|----------------|---------|
| Total urine volume (ml/day)    | 1684.7 ± 788.5 | 1669.1 ± 691.2 | 0.4543  |
| Mean voided volume (ml)       | 169.7 ± 52.8   | 187.0 ± 67.0   | 0.0538  |
| Maximal voided volume (ml)    | 331.5 ± 140.3  | 373.0 ± 139.0  | 0.0424* |
| Minimal voided volume (ml)    | 58.3 ± 31.4    | 72.8 ± 50.2    | 0.0948  |
| Total urinary frequency (/day) | 10.9 ± 3.5     | 9.8 ± 2.7      | 0.0065**|
| Day-time urinary frequency (/6–22 o'clock) | 8.9 ± 2.7 | 7.9 ± 1.7      | 0.0162* |
| Night-time urinary frequency (/22–6 o'clock) | 2.0 ± 1.7 | 1.8 ± 1.6      | 0.1898  |

Objective results of ao-dake-humi on LUTS. One of 21 patients did not make ao-dake-humi-diary
LUTS: lower urinary tract symptoms. *: p < 0.05, ** p < 0.01

dake-humi consists of a half-pipe-shaped foot-step made of bamboo cut into pieces 30–40 cm in length, and is widely used in Japan. The mechanisms of ao-dake-humi promoting general health are not yet known. However, neuromodulation and acupuncture may have similar mechanisms of action on LUTS, constipation and HC. Therefore, the effect of ao-dake-humi is thought not to be due to exercise but to stimulation of afferent nerves in the foot to modulate visceral organs, such as the urinary bladder and colon. Indeed, some neuromodulation equipment has been reported for treatment of LUTS, constipation and faecal incontinence [12]. Electrical stimulation [13–18], magnetic stimulation [19–22] and interferential therapy [23, 24] are mainly used for modulation via the sacral nerve or tibial nerve. Although the precise mechanisms of neuromodulation are not yet known, activation of afferent nerves may lead to activation of efferent nerves in the pelvic organs, including the urinary bladder and colon [13, 14]. Physical stimulation, such as acupuncture, reflexology or foot massage, can be used as a source of neuromodulation via activation of sensory afferent pathways. In addition, the theory of reflexology, including acupuncture, can also be adapted for ao-dake-humi, and our hypothesis about ao-dake-humi is described on Fig. 1a also. In reflexology, areas of the foot are believed to correspond to the organs or structures of the body [25]. Acupuncture was reported to be effective for LUTS and constipation [26–30]. Moreover, in accordance with the foot chart of oriental foot massage, the urinary bladder and colon are located in the “hot spot” of ao-dake-humi stimulation (Fig. 1b). Of course, the exercise effect of ao-dake-humi cannot be completely excluded in this study. Therefore, an RCT should be done between step-work-exercise versus ao-dake-humi.

Ao-dake-humi has many advantages, such as its inexpensiveness, portability, and less risk of harm, compared to other interventions, including electrical neuromodulation. Ao-dake-humi costs about 5 dollars, and requires little maintenance. Moreover, as ao-dake-humi can be shared, it can be used in public spaces, such as hospitals and nursing homes. Ao-dake-humi is lightweight (almost 300 g), and is therefore easily portable, and ideal for daily use at home. Even in comparison with other similar treatments, including acupuncture and massage, ao-dake-humi has advantages. For example, the amount of stimulation can be controlled procedure-dependently in normal foot massage. In contrast, the amount of stimulation of ao-dake-humi is controlled according to body-weight and of each patient. The average body mass index of the participants was 21.8 kg/m², and obese participants were not included in this study. Although adequate methods should be proposed for participants with obesity in future studies, ao-dake-humi can standardise the amount of stimulation for patients. Adverse events associated with neuromodulation, such as infection, bleeding, pain, etc., have been reported [31, 32]. In this study, only three participants complained of slight pain due to ao-dake-humi use, and 98.5% of participants achieved use of ao-dake-humi according to a review of their diaries. All of the participants wished to continue ao-dake-humi use after this study. Even the participants that complained of slight pain at commencement of this study eventually felt comfortable with ao-dake-humi stimulation. There were no severe adverse events, such as diarrhea or urinary retention, among the participants. Of course, on theoretical grounds, it is impossible for the participants to have any severe advised events associated with use of ao-dake-humi. Compared with other neuromodulators, this is the unquestionable advantage of ao-dake-humi in management of LUTS and constipation.

However, this study had some limitations. In this pilot study, 2 sets/day of 2 min of ao-dake-humi were done for 28 days. There have been no reports regarding adequate use of ao-dake-humi. Time, duration, and frequency should be evaluated in future studies. The most important limitation of this study is bias because of its single-arm nature. Subjective results, such as IPSS and OABSS, should be interpreted carefully. However,
objective results from FVC indicated that ao-dake-humi has efficacy for LUTS. Of course, objective evaluation should be performed even for constipation and HC, and more objective evaluation for LUTS, including uroflowmetry, residual urine volume, and cystometry, should also be performed in future studies. Lack of objective evaluation of constipation and HC is also a limitation of this study. However, object evaluation for constipation without any intervention is difficult, and objective measurement of HC has not been established yet. Further investigation is needed to evaluate the exact role of ao-dake-humi on constipation and HC. However, even with these limitations, ao-dake-humi showed statistically relevant subjective and objective results in this study, and there were no adverse events. Thus, ao-dake-humi is a candidate of therapeutic option for LUTS, constipation and HC.

**Conclusions**

The results of this pilot study indicated that ao-dake-humi improved subjective symptoms of LUTS, constipation and HC. Ao-dake-humi also increased maximal voided volume leading to a reduction in urinary frequency without any severe adverse events.

**Abbreviations**

FVC: Frequency-volume-chart; HC: Hypersensitivity to cold; IPSS: International prostate symptom score; LUTS: Lower urinary tract symptoms; OABSS: Overactive bladder symptom score; QoL: Quality of life

**Acknowledgements**

Not applicable.

**Funding**

None.

**Availability of data and materials**

All of data generated or analysed during this study are included in this published article.

**Authors’ contributions**

TM designed the study with OI, carried out the studies, participated in collecting data, performed the statistical analysis, and drafted the manuscript. TS, TD, HY, MI, SH, TN, and MN participated in acquisition of data. TO and OI supervised this trial. TM analysed the data; all authors revised the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors of this paper have no financial or commercial interests to disclose.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Written informed consent was obtained from all participants prior to inclusion in the study. The protocol of this study was approved by the ethics committee of Shinshu University School of Medicine (Permission No. 2184, 2012).

Received: 12 November 2015 Accepted: 24 November 2016

**References**

1. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(9):1582–91. quiz 1581, 1592.
2. Minagawa T, Ishizuka O. Status of urological Kampo medicine: a narrative review and future vision. Int J Urol. 2015;22(3):254–63.
3. Terasawa K. Evidence-based reconstruction of kampo medicine: part II—the concept of Sho. Evid Based Complement Alternat Med. 2004;1(2):119–23.
4. FitzGerald MP, Anderson RJ, Potts J, Payne CK, Peters KM, Clemens JQ, Kotarinos R, Fraser L, Cosby A, Fortman C, et al. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol. 2009;182(2):S70–80.
5. Mak HL, Cheon WC, Wong T, Liu YS, Tong WM. Randomized controlled trial of foot reflexology for patients with symptomatic idiopathic detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(6):653–8.
6. Siev-Ner I, Gamus D, Lerner-Geva L, Achiron A. Reflexology treatment relieves symptoms of multiple sclerosis: a randomized controlled study. Mult Scler. 2009;15(6):536–61.
7. Bishop E, McKinnon E, Weir E, Brown DW. Reflexology in the management of encopresis and chronic constipation. Paediatr Nurs. 2003;15(5):20–1.
8. Barry MJ, Fowler Jr FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK, Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148(5):1549–57. discussion 1564.
9. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamamahi T, Yamaguchi O, Takada M, Nishizawa O. Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score. Urol. 2006;68(2):318–26.
10. Immamura T, Ishizuka O, Nishizawa O. Cold stress induces lower urinary tract symptoms. Int J Urol. 2013;20(7):661–9.
11. Inoue H, Ishizuka H, Immamura T. Relationship between toe temperature and lower urinary tract symptoms. Urol. 2012;144–9.
12. Yamanishi T, Kamai T, Yoshida K. Neuromodulation for the treatment of urinary incontinence. Int J Urol. 2008;15(8):665–72.
13. Shaker HS, Hassouna M. Sacral nerve root neuromodulation: an effective treatment for refractory urge incontinence. J Urol. 1998;159(5):1516–9.
14. Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Suda S. Randomized, double-blind study of electrical stimulation for urinary incontinence due to detrusor overactivity. Urology. 2000;55(3):353–7.
15. Igbal F, Collins B, Thomas GP, Askari A, Tan E, Nicholls RJ, Vaizey CJ. Bilateral transcutaneous nerve stimulation for chronic constipation. Colorectal Dis. 2016;18(2):173–8. doi:10.1111/codi.13105.
16. European SNSBSG. Sacral nerve stimulation for faecal incontinence and constipation a European consensus statement. Color Dis. 2015;17(4):O74–87.
17. Rimmer CJ, Knowles CH, Lamparelli M, Durden P, Lindsey I, Hunt L, Nugent K, Gill KA. Short-term outcomes of a randomized pilot trial of 2 treatment regimens of transcutaneous nerve stimulation for fecal incontinence. Dis Colon Rectum. 2015;58(10):974–82.
18. Thomas GP, Dueland-Jakobsen J, Dudding TC, Bradshaw E, Nicholls RJ, Alam A, Emmanuel A, Thin N, Knowles CH, Laurberg S, et al. A double-blinded randomized multicentre study to investigate the effect of changes in stimulation parameters on sacral nerve stimulation for constipation. Color Dis. 2015;17(11):990–5.
19. Bradshaw HD, Barker AT, Radley SC, Chapple CR. The acute effect of magnetic stimulation of the pelvic floor on involuntary detrusor activity during natural filling and overactive bladder symptoms. BJU Int. 2003;91(9):810–3.
20. Yamanishi T, Homma Y, Nishizawa O, Yasuda K, Yokoyama O, Group S-XS. Multicenter, randomized, sham-controlled study on the efficacy of magnetic stimulation for women with urgency urinary incontinence. Int J Urol. 2014;21(4):395–400.
21. Yamanishi T, Yasuda K, Suda S, Ishikawa N, Sakakibara R, Hattori T. Effect of functional continuous magnetic stimulation for urinary incontinence. J Urol. 2000;163(2):456–9.
22. Yokoyama T, Fujita O, Nishiguchi N, Nozaki K, Nose H, Inoue M, Ozawa H, Kumon H. Extracorporeal magnetic innervation treatment for urinary incontinence. Int J Urol. 2004;11(8):602–6.
23. Van Poppel H, Ketelaar P, Van DeWeerd A. Interferential therapy for detrusor hyperreflexia in multiple sclerosis. Urology. 1985;25(6):607–12.
24. Oh-Oka H. Efficacy of interferential low frequency therapy for elderly wet overactive bladder patients. Indian journal of urology. 2008;24(2):178–81.
25. Vickers A, Zollman C. ABC of complementary medicine. Massage therapies. BMJ. 1999;319(7219):1254-7.
26. Aydogmus Y, Sunay M, Arslan H, Aydin A, Adiloglu AK, Sahin H. Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial. Urol Int. 2014;93(4):437-43.
27. Emmons SL, Otto L. Acupuncture for overactive bladder: a randomized controlled trial. Obstet Gynecol. 2005;106(1):138-43.
28. Paik SH, Han SR, Kwon OJ, Ahn YM, Lee BC, Ahn SY. Acupuncture for the treatment of urinary incontinence: A review of randomized controlled trials. Experimental and therapeutic medicine. 2013;6(3):773-80.
29. Yuan Z, He C, Yan S, Huang D, Wang H, Tang W. Acupuncture for overactive bladder in female adult: a randomized controlled trial. World J Urol. 2015;33(9):1303-8.
30. Zheng Q, Zheng H, Lu L, Leng J, Zhou S, Zheng H, Huang W, Liu Z, Zhu B, Li Y. Acupuncture for functional constipation: protocol of an individual patient data meta-analysis. BMJ Open. 2015;5(5):e007137.
31. Kessler TM, Buchser E, Meyer S, Engeler DS, Al-Khodairi AW, Berch U, Iselin CE, Roche B, Schmid DM, Schurch B, et al. Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland. Eur Urol. 2007;51(5):1357-63.
32. Marcelissen TA, Leong RK, de Bie RA, van Kerrebroeck PE, de Wachter SG. Long-term results of sacral neuromodulation with the tined lead procedure. J Urol. 2010;184(5):1997-2000.